BRIEF published on 12/19/2024 at 22:10, 1 day 20 hours ago Protagonist Therapeutics présentera ses produits à la conférence JP Morgan Healthcare Rusfertide Thérapeutique Protagoniste Icotrokinra Développement Biopharmaceutique Conférence De JP Morgan
BRIEF published on 12/19/2024 at 22:10, 1 day 20 hours ago Protagonist Therapeutics to Present at J.P. Morgan Healthcare Conference Protagonist Therapeutics Rusfertide Icotrokinra Biopharmaceutical Development J.P. Morgan Conference
PRESS RELEASE published on 12/19/2024 at 22:05, 1 day 20 hours ago Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 Protagonist Therapeutics to present company overview at 43rd Annual J.P. Morgan Healthcare Conference. Highlights late-stage peptides in clinical development Clinical Development Biopharmaceutical Protagonist Therapeutics J.P. Morgan Healthcare Conference Peptides
BRIEF published on 12/09/2024 at 22:10, 11 days 20 hours ago Protagonist Therapeutics révèle des résultats prometteurs pour son étude sur le rusfertide à l'ASH 2024 Rusfertide Polycythémie Vraie Phase 2 REVIVE ASH 2024 Contrôle De L'hématocrite
BRIEF published on 12/09/2024 at 22:10, 11 days 20 hours ago Protagonist Therapeutics Reveals Promising Rusfertide Study Results at ASH 2024 Rusfertide Polycythemia Vera Phase 2 REVIVE Hematocrit Control ASH 2024
PRESS RELEASE published on 12/09/2024 at 22:05, 11 days 20 hours ago Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting Protagonist Therapeutics announced positive final data from rusfertide Phase 2 REVIVE study for treating polycythemia vera, presented at ASH 2024 Protagonist Therapeutics Rusfertide Polycythemia Vera Hematocrit Control REVIVE Study
BRIEF published on 11/22/2024 at 13:35, 29 days 5 hours ago Protagonist Therapeutics participera à la conférence Evercore ISI HealthCONx Essais Cliniques Thérapeutique Protagoniste Participation À La Conférence Evercore ISI HealthCONx Développement Biopharmaceutique
BRIEF published on 11/22/2024 at 13:35, 29 days 5 hours ago Protagonist Therapeutics to Engage at Evercore ISI HealthCONx Conference Clinical Trials Protagonist Therapeutics Conference Participation Evercore ISI HealthCONx Biopharmaceutical Development
PRESS RELEASE published on 11/22/2024 at 13:30, 29 days 5 hours ago Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 Protagonist Therapeutics to participate in fireside chat at 7th Annual Evercore ISI HealthCONx Conference on Dec 3-5, 2024. Company's CEO, Dinesh V. Patel, to discuss latest developments Biopharmaceutical Fireside Chat Protagonist Therapeutics Evercore ISI HealthCONx Conference Dinesh V. Patel
BRIEF published on 11/21/2024 at 22:10, 29 days 20 hours ago Protagonist Therapeutics Nominates PN-881 for Immune-Mediated Skin Disorders Protagonist Therapeutics IL-17 Antagonist PN-881 Skin Diseases Phase I Trials
Published on 12/21/2024 at 01:30, 17 hours 31 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 31 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 56 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 19 hours 31 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 18 hours 10 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 16 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 51 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:00, 1 day 1 hour ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 6 hours 44 minutes ago AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 6 hours 44 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024
